Molecular mechanisms of angiogenesis in non‐small cell lung cancer, and therapeutics targeting related molecules
Molecular mechanisms of angiogenesis in non‐small cell lung cancer, and therapeutics targeting related molecules
复制标题
DOI：
10.1111/j.1349-7006.2003.tb01469.x
复制
发表时间：
2003-06
期刊：
影响因子：
5.7
通讯作者：
S. Yano;Y. Nishioka;H. Goto;S. Sone
中科院分区：
文献类型：
--
作者：
S. Yano;Y. Nishioka;H. Goto;S. Sone
血管生成，即来自既存血管的新血管形成，是为原发器官和远端器官中的肿瘤生长提供氧气和营养所必需的。它包括萌芽和非萌芽（既存血管的扩大，分裂和融合）过程，两者可以同时发生。包括非小细胞肺癌（NSCLC）在内的实体瘤的生长通常依赖于血管生成，而血管生成受到涉及各种血管生成相关分子的复杂机制的调节。血管内皮生长因子（VEGF），也称为血管通透性因子（VPF），是最有效的血管生成分子之一，调节血管生成和血管通透性，因此促进NSCLC中肿瘤进展和恶性胸腔积液的发展。表皮生长因子受体（EGFR）信号不仅促进肿瘤细胞周期，而且促进血管生成过程。因此，这些分子是抗肿瘤血管治疗的潜在靶点。已经开发了许多靶向肿瘤血管的药物，并且一些化合物在临床前研究中显示出抗肿瘤潜力。目前正在临床试验中评估其对NSCLC的疗效。
Angiogenesis, neovascularization from pre‐existing vasculature, is necessary to supply oxygen and nutrition for tumor growth in both primary and distant organs. It consists of sprouting and non‐sprouting (the enlargement, splitting, and fusion of pre‐existing vessels) processes, and both can occur concurrently. Growth of solid tumors, including non‐small cell lung cancer (NSCLC), is usually dependent on angiogenesis, which is regulated by complex mechanisms involving various angiogenesis‐related molecules. Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), one of the most potent angiogenic molecules, regulates both angiogenesis and vascular permeability, and hence promotes tumor progression and development of malignant pleural effusions in NSCLC. Signals via epidermal growth factor receptor (EGFR) promote not only the tumor cell cycle, but also the process of angiogenesis. Therefore, these molecules are potential targets for anti‐tumor vasculature therapy. Many agents targeting tumor vasculature have been developed, and several compounds have shown anti‐tumor potential in pre‐clinical studies. Their efficacy against NSCLC is currently being evaluated in clinical trials.